Gilead's NDA for ambrisentan damages Encysive shares

With its NDA for Thelin hung up at the FDA, Encysive saw its stock price slip after Gilead announced that the agency had accepted its application for a competing pulmonary arterial hypertension drug, ambrisentan. The FDA is giving ambrisentan a priority review. Analysts criticized Encysive for losing its lead over ambrisentan. Thelin has been approved in Europe but its FDA application has been delayed a by year.

- here's the AP report on the competition

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.